These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 1987374)

  • 1. Effectiveness of enteric immunization in the development of secretory immunoglobulin A response and the outcome of infection with respiratory syncytial virus.
    Kanesaki T; Murphy BR; Collins PL; Ogra PL
    J Virol; 1991 Feb; 65(2):657-63. PubMed ID: 1987374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia--RSV recombinants or RSV.
    Connors M; Collins PL; Firestone CY; Sotnikov AV; Waitze A; Davis AR; Hung PP; Chanock RM; Murphy BR
    Vaccine; 1992; 10(7):475-84. PubMed ID: 1609551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics of immunity induced by viral antigen or conferred by antibody via different administration routes.
    Matsuoka T; Okamoto Y; Matsuzaki Z; Endo S; Ito E; Tsutsumi H; Williamson RA; Sakurai H; Burton DR; Saito I
    Clin Exp Immunol; 2002 Dec; 130(3):386-92. PubMed ID: 12452827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid recovery in mice after combined nasal/oral immunization with killed respiratory syncytial virus.
    Reuman PD; Keely SP; Schiff GM
    J Med Virol; 1990 Sep; 32(1):67-72. PubMed ID: 2243208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of an intranasal virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice and cotton rats.
    Kamphuis T; Shafique M; Meijerhof T; Stegmann T; Wilschut J; de Haan A
    Vaccine; 2013 Apr; 31(17):2169-76. PubMed ID: 23499594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunosuppression of the antibody response to respiratory syncytial virus (RSV) by pre-existing serum antibodies: partial prevention by topical infection of the respiratory tract with vaccinia virus-RSV recombinants.
    Murphy BR; Collins PL; Lawrence L; Zubak J; Chanock RM; Prince GA
    J Gen Virol; 1989 Aug; 70 ( Pt 8)():2185-90. PubMed ID: 2671259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance to human respiratory syncytial virus (RSV) infection induced by immunization of cotton rats with a recombinant vaccinia virus expressing the RSV G glycoprotein.
    Elango N; Prince GA; Murphy BR; Venkatesan S; Chanock RM; Moss B
    Proc Natl Acad Sci U S A; 1986 Mar; 83(6):1906-10. PubMed ID: 3513191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum and nasal-wash immunoglobulin G and A antibody response of infants and children to respiratory syncytial virus F and G glycoproteins following primary infection.
    Murphy BR; Graham BS; Prince GA; Walsh EE; Chanock RM; Karzon DT; Wright PF
    J Clin Microbiol; 1986 Jun; 23(6):1009-14. PubMed ID: 3754878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats.
    Widjojoatmodjo MN; Bogaert L; Meek B; Zahn R; Vellinga J; Custers J; Serroyen J; Radošević K; Schuitemaker H
    Vaccine; 2015 Oct; 33(41):5406-5414. PubMed ID: 26319741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization.
    Murphy BR; Sotnikov AV; Lawrence LA; Banks SM; Prince GA
    Vaccine; 1990 Oct; 8(5):497-502. PubMed ID: 2251875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge.
    Wang D; Phan S; DiStefano DJ; Citron MP; Callahan CL; Indrawati L; Dubey SA; Heidecker GJ; Govindarajan D; Liang X; He B; Espeseth AS
    J Virol; 2017 Jun; 91(11):. PubMed ID: 28298602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intranasal immunization with a replication-deficient adenoviral vector expressing the fusion glycoprotein of respiratory syncytial virus elicits protective immunity in BALB/c mice.
    Fu Y; He J; Zheng X; Wu Q; Zhang M; Wang X; Wang Y; Xie C; Tang Q; Wei W; Wang M; Song J; Qu J; Zhang Y; Wang X; Hong T
    Biochem Biophys Res Commun; 2009 Apr; 381(4):528-32. PubMed ID: 19233131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intranasal monoclonal immunoglobulin A against respiratory syncytial virus protects against upper and lower respiratory tract infections in mice.
    Weltzin R; Hsu SA; Mittler ES; Georgakopoulos K; Monath TP
    Antimicrob Agents Chemother; 1994 Dec; 38(12):2785-91. PubMed ID: 7695263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antigenic relatedness between glycoproteins of human respiratory syncytial virus subgroups A and B: evaluation of the contributions of F and G glycoproteins to immunity.
    Johnson PR; Olmsted RA; Prince GA; Murphy BR; Alling DW; Walsh EE; Collins PL
    J Virol; 1987 Oct; 61(10):3163-6. PubMed ID: 3305988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistance to respiratory syncytial virus (RSV) challenge induced by infection with a vaccinia virus recombinant expressing the RSV M2 protein (Vac-M2) is mediated by CD8+ T cells, while that induced by Vac-F or Vac-G recombinants is mediated by antibodies.
    Connors M; Kulkarni AB; Collins PL; Firestone CY; Holmes KL; Morse HC; Murphy BR
    J Virol; 1992 Feb; 66(2):1277-81. PubMed ID: 1731105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune and histopathological responses in animals vaccinated with recombinant vaccinia viruses that express individual genes of human respiratory syncytial virus.
    Stott EJ; Taylor G; Ball LA; Anderson K; Young KK; King AM; Wertz GW
    J Virol; 1987 Dec; 61(12):3855-61. PubMed ID: 3316707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A chimeric glycoprotein formulated with a combination adjuvant induces protective immunity against both human respiratory syncytial virus and parainfluenza virus type 3.
    Garg R; Brownlie R; Latimer L; Gerdts V; Potter A; van Drunen Littel-van den Hurk S
    Antiviral Res; 2018 Oct; 158():78-87. PubMed ID: 30071204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intranasal monoclonal IgA antibody to respiratory syncytial virus protects rhesus monkeys against upper and lower respiratory tract infection.
    Weltzin R; Traina-Dorge V; Soike K; Zhang JY; Mack P; Soman G; Drabik G; Monath TP
    J Infect Dis; 1996 Aug; 174(2):256-61. PubMed ID: 8699052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of mucosal B-cell memory by intranasal immunization of mice with respiratory syncytial virus.
    Valosky J; Hishiki H; Zaoutis TE; Coffin SE
    Clin Diagn Lab Immunol; 2005 Jan; 12(1):171-9. PubMed ID: 15643003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secretory antibody response to respiratory syncytial virus infection.
    Kaul TN; Welliver RC; Wong DT; Udwadia RA; Riddlesberger K; Ogra PL
    Am J Dis Child; 1981 Nov; 135(11):1013-6. PubMed ID: 7294005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.